New hope for advanced melanoma: immunotherapy combo tested in india

NCT ID NCT07459543

Not yet recruiting Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will take part. This is an early safety-focused study, not a cure, but it may offer a new treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MELANOMA UNRESECTABLE MELANOMA UNTREATED MELANOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Local Institution - 0001

New Delhi, 110085, India

Contact
Local Institution - 0002

Chennai, 600006, India

Contact
Local Institution - 0003

Bhubaneswar, Odisha, 751007, India

Contact
Local Institution - 0004

New Delhi, 110029, India

Contact
Local Institution - 0005

Nagpur, 440001, India

Contact
Local Institution - 0006

Mumbai, 400 012, India

Contact
Local Institution - 0008

Pune, Maharashtra, 411017, India

Contact
Local Institution - 0009

Navi Mumbai, Maharashtra, 400614, India

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.